Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

XClose

Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø Division of Medicine

Home
Menu

Fragile X treatment licensed to Lenire Biosciences by Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

23 June 2022

Fragile X syndrome (FXS) is the most common genetically linked cause of intellectual disabilities and autism

Part extracellular view of the BK Channel, residues coloured as space-filling are associated with deficiencies in channel function.

Fragile X syndrome (FXS)Ìýis a neurodevelopmental condition occurring due to a CGG trinucleotide expansion in the FMR1 gene. Polymorphisms and variants in large-conductance calcium-activated potassium channels are increasingly linked to intellectual disability and loss of FMR protein causes reduced large-conductance calcium-activated potassium channel activity leading to abnormalities in synapse function.

Using the endo-cannabinoid-like large-conductance calcium-activated potassium channel activator VSN16R, designed in our lab we rescued behavioural deficits such as repetitive behaviour, hippocampal dependent tests of daily living, hyperactivity and memory in a mouse model of fragile X syndrome (Study published in Brain 2021).

VSN16R was designed and synthesised in the Selwood lab at Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø by Cristina Visintin and Masahiro Takahiro and originally developed for Multiple Sclerosis. First studies in people with Fragile X are expected in 2023.

News articles

Publication

  • 'Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice'Ìý Brain, Volume 145, Issue 1, January 2022, Pages 76–82,Ìý

Wolfson Institute for Biomedical Research Neurosciences (WIBR), Division of Medicine